Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

MicroRNAs may play a key role in future medicine

Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled "MicroRNAs: A Potential New Frontier for Medicine," an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.

24 Mar 2011

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Nordion Inc., a leading provider of products and services to the global health science market, today announced that it has received U.S. Food and Drug Administration approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption.

23 Mar 2011

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

The University of Texas MD Anderson Cancer Center has been awarded a grant to study whether xerostomia, a debilitating side effect caused by head and neck cancer radiation treatment, can be prevented when acupuncture is part of a patient's treatment regimen.

23 Mar 2011

Researchers discover novel gene regulation mechanism that contributes to HCC development

Researchers at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma.

23 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Genentech, a member of the Roche Group, today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

21 Mar 2011

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.

19 Mar 2011

Researchers review patient outcomes from full, partial organ removal for kidney cancer

Patients with kidney cancer who had their entire organ removed were more likely to have more renal complications and poorer health after surgery, compared to those who had only part of their kidney removed, a study has shown.

19 Mar 2011

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20, the company's novel enzyme-based treatment for malignant mesothelioma.

19 Mar 2011

Olympus offers new stones retrieval products

Over the last years, the equipment for endoscopy and training of ureteroscopy has improved significantly. The shift from ESWL to ureteroscopy is evident.

From Evident Corporation - Life Sciences 18 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Conservative approach with endoscopic techniques can resolve colonic perforation

Colonoscopy is considered a safe procedure, although complications can occur. The most dreaded of these is iatrogenic perforation. The literature reports perforation rates of 0.03%-0.8% for diagnostic procedures, and a rate of 0.15%-3% for therapeutic procedures.

16 Mar 2011

Research: Underweight HCV-infected patients tend to be older at HCC onset

The incidence and mortality associated with hepatocellular carcinoma have been increasing worldwide, and hepatitis C virus infection plays an important role in the pathogenesis of HCC.

16 Mar 2011

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the updated NCCN Guidelines for Ovarian Cancer, are vital to making steady progress against the disease according to Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Ovarian Cancer.

16 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Research highlights benefit of shortened radiation course for patients with DCIS

Findings by a researcher at The Cancer Institute of New Jersey highlighting the benefit of a shortened radiation course for patients with the most common type of non-invasive breast cancer are part of a feature article in the journal Cancer due out tomorrow.

15 Mar 2011

EASL schedules press conference and news briefings during International Liver Congress 2011

The EASL International Liver Congress is an opportunity for over 6,000 clinicians and scientists from around the world to hear the latest research, perspectives and treatments for liver diseases from principal experts in the field. It features a high-calibre and multi-disciplinary scientific programme covering groundbreaking information and in-depth examination of the most essential topics.

14 Mar 2011

Women with DCIS have excellent overall prognosis despite treatment

Women with ductal carcinoma in situ-DCIS-who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.

14 Mar 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Carcinoma News and Research

Further Reading

MicroRNAs may play a key role in future medicine

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

Researchers discover novel gene regulation mechanism that contributes to HCC development

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

Researchers review patient outcomes from full, partial organ removal for kidney cancer

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Olympus offers new stones retrieval products

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Conservative approach with endoscopic techniques can resolve colonic perforation

Research: Underweight HCV-infected patients tend to be older at HCC onset

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Omeros fourth quarter net loss increases to $7.2 million

Research highlights benefit of shortened radiation course for patients with DCIS

EASL schedules press conference and news briefings during International Liver Congress 2011

Women with DCIS have excellent overall prognosis despite treatment

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Idera reports $6.0 million net loss for fourth quarter 2010

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News